FDA warned Max Chemical Inc. in San Juan, Puerto Rico, that its OTC drug manufacturing violated CGMP, making its drugs adulterated.
What happened
FDA inspected Max Chemical Inc.'s drug manufacturing facility in San Juan, Puerto Rico, from March 11 to 15, 2024. Investigators found the firm did not test each incoming component lot for identity, used water in its OTC drugs from a water system that was not qualified or monitored, and had a quality unit that did not carry out its oversight duties. The firm's April 3, 2024 response was inadequate because it lacked supporting documentation and evidence of corrective actions.
What FDA found
The firm did not run an identity test on each shipment of each component, including its active ingredients, and relied on supplier certificates of analysis without proving those certificates were reliable.
21 CFR 211.84(d)(1) and 211.84(d)(2)The firm had no written procedures for production and process control, and its water system was not qualified or monitored even though water is used in its OTC drugs.
21 CFR 211.100(a)The quality unit failed to make sure finished products were adequately tested.
21 CFR 211.22; 211.165(a) and 211.165(b)The quality unit failed to set up an adequate stability program.
21 CFR 211.137(a)The quality unit failed to ensure in-process testing failures were adequately investigated.
21 CFR 211.192The quality unit failed to ensure employees involved in making, processing, packing or holding drugs were adequately trained.
21 CFR 211.25(a)
What FDA wants
FDA asks the firm to reply in writing within 15 working days, on company letterhead, saying what it has done to fix the violations and prevent them from recurring. The firm must also notify FDA before resuming any drug manufacturing and, if it resumes, should hire a qualified consultant to audit its operations.
Who should pay attention
- distributors and retailers selling this firm's OTC drug products
- brands that contract with Puerto Rico-based OTC drug manufacturers
- companies that buy alcohol-based OTC drug products from contract manufacturers
This is a summary. Read the original letter on fda.gov.